On November 5, 1993, the Food and Drug Administration (FDA) approved genetically engineered Artificial Bovine Growth Hormone (rBST, rBGH, BGH) for commercial use in the United States.
“In March 1993, before rbST was approved, an FDA advisory committee concluded that the use of rbST — and any increased risk of mastitis and resulting increased use of antibiotics in treated cattle — would not pose a risk to human health.
Monsanto Co.’s Posilac, the only rbST product approved for increasing milk production in dairy cattle, was first marketed in February 1994.”